Table 2: Characteristics
of 21 patients with peripheral T-cell lymphoma and long-term remission after ASCT.
|
Patients,
n |
21 |
|
Age
(years, median/range) |
54
(19-73) |
|
Sex
(female/male), n (%) |
8
(38) / 13 (62) |
|
Histology: Anaplastic Large-Cell Lymphoma, 5 of whom ALK-, 5
ALK+, 2 ALK not tested, n (%) Peripheral T-Cell Lymphoma
(NOS and similar), n (%) Angioimmunoblastic T-Cell
Lymphoma, n (%) Enteropathy-Associated
T-Cell Lymphoma, n (%) Stage
(Ann Arbor) 1st-line ASCT: I (enteropathy-associated TL), n (%)
II, n (%) III, n (%)
IV, n (%) IPI
at 1st-line chemotherapy: low risk, n (%)
low-intermediate risk, n (%) high-intermediate risk,
n (%)
high risk, n (%) |
12
(57) 4(17) 4
(17) 1
(5) 1
(5) 3
(14) 5
(24) 2
(10) 7
(33) 2(10) 1 (5) 1 (5) |
|
Prior
treatment with anthracyclines (CHOP or CHOEP), n (%) |
21
(100) |
|
High-dose
therapy: BEAM Mega-CHOEP
TBI/Cyclophosphamide Treatment
line: 1st-line ASCT, n (%) 2nd-line
ASCT, n (%) 3rd-line
ASCT, n (%) Time
from initial diagnosis to 1st relapse in 2nd-line ASCT,
median/range (mo) |
20
(95) 0 1 (5) 11
(52) 7
(33) 3
(14) 25
(4-123) |
|
Time
from initial diagnosis to 1st relapse in 3rd-line ASCT,
median/range (mo) Refractory
to 2nd-line chemotherapy, n (%) Second
relapse, n (%) LDH:
elevated at 1st-line ASCT, n (%),
elevated at 2nd-line
ASCT, n (%), elevated at 3rd-line
ASCT, n (%), |
5
(1-9) 3
(14) 0 1
(9) 1
(14) 0 |
|
Remission
status: CR/PR/SD/PD at 1st-line ASCT, n CR/PR/SD/PD
after 1st-line ASCT, n CR/PR/SD/PD at
2nd-line ASCT, n CR/PR/SD/PD/ED
after 2nd-line ASCT, n CR/PR/SD/PD at
3rd-line ASCT, n
CR/PR/SD/PD/ED/NI after 3rd-line ASCT, n |
2/9/0/0 3/8/0/0 5/2/0/0 7/0/0/0 0/0/1/2 2/1/0/0 |
|
Radiotherapy
after 1st-line ASCT, n (%) Radiotherapy
after 2nd-line ASCT, n (%) Radiotherapy
after 3rd-line ASCT, n (%) Allogeneic
stem cell transplantation |
3
(27) 2
(29) 2
(67) 0 |
ALK:
Anaplastic Lymphoma Kinase; TL: T-cell Lymphoma; NOS: Not Otherwise Specified;
IPI: International Prognostic Index; BEAM: High-dose BCNU, Etoposide,
Cytarabine, Melphalan; Mega-CHOEP: High-dose Cyclophosphamide, Doxorubicin,
Vincristine, Etoposide, Prednisone; TBI: Total Body Irradiation; mo: Months;
LDH: Lactic Dehydrogenase; CR: Complete Remission; PR: Partial Remission; SD:
Stable Disease; PD: Progressive Disease; ED: Early Death; NI: No Information.